The CYTR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CYTR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CYTR Detailed Price Forecast - CNN Money||View CYTR Detailed Summary - Google Finance|
|View CYTR Detailed Summary - Yahoo! Finance||View CYTR Stock Research & Analysis - Zacks.com|
|View CYTR Trends & Analysis - Trade-Ideas||View CYTR Major Holders - Barrons|
|View CYTR Call Transcripts - NASDAQ||View CYTR Breaking News & Analysis - Seeking Alpha|
|View CYTR Annual Report - CompanySpotlight.com||View CYTR OTC Short Report - OTCShortReport.com|
|View CYTR Fundamentals - TradeKing||View CYTR SEC Filings - Bar Chart|
|View Historical Prices for CYTR - The WSJ||View Performance/Total Return for CYTR - Morningstar|
|View the Analyst Estimates for CYTR - MarketWatch||View the Earnings History for CYTR - CNBC|
|View the CYTR Earnings - StockMarketWatch||View CYTR Buy or Sell Recommendations - MacroAxis|
|View the CYTR Bullish Patterns - American Bulls||View CYTR Short Pain Metrics - ShortPainBot.com|
|View CYTR Stock Mentions - StockTwits||View CYTR Stock Mentions - PennyStockTweets|
|View CYTR Stock Mentions - Twitter||View CYTR Investment Forum News - Investor Hub|
|View CYTR Stock Mentions - Yahoo! Message Board||View CYTR Stock Mentions - Seeking Alpha|
|View Insider Transactions for CYTR - SECform4.com||View Insider Transactions for CYTR - Insider Cow|
|View CYTR Major Holdings Summary - CNBC||View Insider Disclosure for CYTR - OTC Markets|
|View Insider Transactions for CYTR - Yahoo! Finance||View Institutional Holdings for CYTR - NASDAQ|
|View CYTR Stock Insight & Charts - FinViz.com||View CYTR Investment Charts - StockCharts.com|
|View CYTR Stock Overview & Charts - BarChart||View CYTR User Generated Charts - Trading View|
CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
Posted on Tuesday March 12, 2019
LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors," has been published online in Nuclear Medicine and Molecular Imaging. The abstract may be found and the full article purchased online at https://doi.org/10.1007/s13139-019-00587-w.
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
Posted on Wednesday February 13, 2019
LOS ANGELES, Feb. 13, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for LADR-7 (AE-Keto-Sulf07), one of its lead LADR™ (Linker Activated Drug Release) candidates. The article, entitled "Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound" to be published in the Journal of Controlled Release, a leading journal for drug delivery on February 28, 2019. The abstract may be found and full article purchased online at https://www.sciencedirect.com/journal/journal-of-controlled-release/vol/296.
LOS ANGELES, Feb. 11, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patients do not have targetable genetic mutations that would make them eligible for targeted treatment.
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
Posted on Wednesday February 06, 2019
LOS ANGELES, Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (ORPHA.CO). Orphazyme is currently developing arimoclomol in four different indications, including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).